argenx SE (NASDAQ:ARGX – Get Rating) – Equities researchers at Jefferies Financial Group issued their FY2027 EPS estimates for argenx in a research note issued to investors on Monday, January 9th. Jefferies Financial Group analyst A. Tewari forecasts that the company will post earnings per share of $20.45 for the year. The consensus estimate for argenx’s current full-year earnings is ($15.54) per share.
argenx (NASDAQ:ARGX – Get Rating) last announced its quarterly earnings data on Thursday, October 27th. The company reported ($4.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.50) by ($0.76). The firm had revenue of $146.49 million during the quarter, compared to the consensus estimate of $115.49 million. argenx had a negative net margin of 295.08% and a negative return on equity of 49.53%.
argenx Price Performance
Shares of NASDAQ:ARGX opened at $395.45 on Wednesday. The company’s 50 day simple moving average is $378.14 and its 200 day simple moving average is $372.79. The stock has a market capitalization of $21.88 billion, a price-to-earnings ratio of -23.00 and a beta of 0.80. argenx has a 1 year low of $249.50 and a 1 year high of $407.93.
Hedge Funds Weigh In On argenx
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Fulton Bank N.A. acquired a new position in argenx in the fourth quarter valued at $201,000. BNP Paribas Arbitrage SNC lifted its holdings in argenx by 12,565.0% in the third quarter. BNP Paribas Arbitrage SNC now owns 46,734 shares of the company’s stock valued at $16,499,000 after buying an additional 46,365 shares during the period. Nomura Holdings Inc. bought a new stake in argenx in the third quarter valued at $10,592,000. State Street Corp increased its stake in argenx by 13.6% in the third quarter. State Street Corp now owns 3,018 shares of the company’s stock valued at $1,066,000 after purchasing an additional 361 shares in the last quarter. Finally, Susquehanna International Securities Ltd. bought a new stake in argenx in the third quarter valued at $353,000. Institutional investors and hedge funds own 57.29% of the company’s stock.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.